Application of serum hepatitis B virus large surface protein determination in lamivudine anti-viral therapy for patients with hepatitis B
10.3760/cma.j.issn.1003-9279.2008.02.018
- VernacularTitle:乙型肝炎病毒大蛋白检测在拉米夫定抗病毒治疗中的应用研究
- Author:
Guang-Yi LI
1
;
Jiang-Lai SHENG
;
Hai-Jun HUANG
Author Information
1. 浙江省安吉县人民医院
- Keywords:
Hepatitis B virus;
Viral envelope proteins;
DNA;
Antiviral agents
- From:
Chinese Journal of Experimental and Clinical Virology
2008;22(2):133-135
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the correlation between serum hepatitis B virus large surface protein (HBV-LP)and hepatitis B virus DNA (HBV-DNA) load in hepatitis B patients treated with lamivudine, and the application of serum HBV-LP measurement in evaluation of lamivudine therapeutic effect and end point judgement.Methods HBV DNA was detected by fluorescent quantitative PCR (FQ-PCR), serum HBV-LP was detected by enzyme linked immunosorbent assay (ELISA). Results Both HBV-DNA and HBV-LP decreased in patients responding to lamivudine therapy, and HBV-LP turned negative 3 months later than HBV-DNA. In patients resistant to lamivudine therapy, neither HBV-DNA nor HBV-LP turned negative. In patients whose symptoms relapsed, HBV-LP didn't turn negative, while HBV-DNA was undetectable only transitorily. Conclusion Measuring serum HBV-LP dynamically can be useful in evaluation of lamivudine therapeutic effect.
